AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test

When giv­en with oth­er can­cer drugs for a lim­it­ed time, As­traZeneca’s Calquence hit the pri­ma­ry end­point in a reg­is­tra­tional test, which could open up a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.